AusBioFEATURE – AusMedtech 2016Australia’s medtech conference toconvene in AdelaideFollowing the success of AusMedtech 2015 in A highlight on day one will be the plenaryMelbourne, this year’s AusMedtech conference delivered by Stephen Tomisich, CEO of Trajanwill move to the Adelaide Convention Centre Scientific and Medical, who has seen theto continue discussions about the issues and company grow from a new entrant to a well-factors relevant to global medtech success. established leader in the Australian medtech industry. Trajan has already made a significantThe conference, presented by AusMedtech with breakthrough in its recent partnership with thehost partners BioSA and the Adelaide Convention University of Adelaide’s Institute for PhotonicsBureau, will celebrate the latest innovations in and Advanced Sensing (IPAS) by openingthe sector, with a spotlight on South Australian a new business unit at the University’s facilitiesingenuity. focusing on instruments, sensors and devices. This milestone expands Trajan’s footprint outsideAusBiotech’s annual AusMedtech event is their HQ in Melbourne and will drive collaborationAustralia’s premier medtech conference for with the University’s technical capabilitiesdevelopers, manufacturers and suppliers of further assisting their vision to enhancemedical technology, from emerging companies, human wellbeing.engineers and clinicians to commercially-successful global companies involved in On day two, Dr Neal Fearnot, President, Cookdevelopment of new medical devices and Advanced Technologies and Vice President,diagnostics. It provides the opportunity to come Cook Group Incorporated, Cook Medical (USA),together and learn from colleagues who share the will present a plenary giving his expert viewchallenges associated with this sector. on the key issues facing the global medtech industry. Neal Fearnot’s focus at Cook MedicalAusMedtech 2016 will feature a comprehensive is the scientific and business potential of newprogram, trade exhibition, networking events and medical technology and regulatory affairs policyAusPartnering, our business matching program worldwide. Among his experience of serving asenabling delegates to schedule 30-minute founding President of three companies – MEDmeetings with other attendees. Institute, Cook Biotech and Cook Advanced Technologies – Dr Fearnot has filed countlessThere will also be an opportunity for delegates submissions to the US Government as well asto join a tour of the Medical Device Research providing input to the development of legislationInstitute (MDRI) at Flinders University in in the US, Japan, India, Taiwan, Europe, Panama,Tonsley, to view some of the research, facilities Bahamas and Mexico.and capabilities within the MDRI and meetacademics driving the research. MDRI is also View the full AusMedtech 2016 program athome to the award-winning Medical Device ausmedtech.com.auPartnering Program (MDPP), a unique model forcollaboration between researchers, clinicians,end-users and industry, responding to industry-driven research problems and connecting ideasto develop innovative medical devices andassistive technologies. The tour is available toregistered delegates only and RSVP is required.The AusMedtech 2016 program will address Akey commercial issues such as exportopportunities, finance and investment, hottechnologies and updates in the fields of IP,rreeigmublautorsreymapenptroavnadlss,ahleesaltnhetewcoorCAnkoousm.nstficreasrleiaann’cdseMedtech Volume 26 • Number 1 • March 2016 Australasian BioTechnology 51
Registernow
AusBioFEATURE – AusMedtech 2016AUSMEDTECH 2016 PARTNERS HOST PARTNERS www.innovationsa.com.au www.adelaideconvention.com.au PARTNERSwww.ajpark.com www.anff.org.au www.bosch.com.au www.cookmedical.comwww.dektech.com.au www.greyinnovation.com www.houlihan2.com www.hydrix.comwww.madderns.com.au www.microsoft.com www.pof.com.au www.quintiles.comwww.revoxsterilization.com www.rsm.global/australia www.westpharma.com KNOWLEDGE PARTNER MEDIA PARTNER www.ww2.frost.com www.venturevaluation.com Volume 26 • Number 1 • March 2016 Australasian BioTechnology 53
AusBioFEATURE – AusMedtech 2016AUSMEDTECH 2016 EXHIBITORSwww.alcidion.com.au www.amslabs.com.au www.apctechnology.com.auwww.assistus.com.au www.innovationsa.com.au www.bosch.com.auwww.csiro.au www.dektech.com.au www.hydrix.comwww.madderns.com.au www.mastercontrol.com www.flinders.edu.au/mdppwww.namsa.com www.quintiles.com www.revoxsterilization.comwww.rsm.global/australia www.seerpharma.com www.sisuwellness.comwww.statek.com www.thermofisher.com.au54 Australasian BioTechnology Volume 26 • Number 1 • March 2016
AusBioFEATURE – AusMedtech 2016Pulse of the across the entire life sciences sector, includingindustry – global medtech, biotechnology and pharmaceuticals.medtech outlook In this environment, the number of IPOs in the Australian sector as a whole remains limited –Gamini Martinus with just five deals announced in the last year, raising less than AU$50m.Australian Life Sciences Leader,Ernst & Young These challenges raise important questions about the long-term sustainability of the sector.The global medical technology sector continues Reigniting revenue growth will require a renewedto face tepid growth and a dwindling pool of focus on the development of breakthroughinvestors for early-stage companies. In the 12 products and solutions that improve healthmonths ending 30 June 2015, these obstacles outcomes. It is those innovations that willwere partially offset by a record number of initial catalyse and sustain investor enthusiasmpublic offerings and debt deals, a healthy market in the medtech industry.for mergers and acquisitions, and an increasedemphasis on R&D spending. But, despite these So it’s heartening to see that innovation is stillgains, the medtech industry cannot afford firmly on the agenda of the Australian medtechcomplacency. sector. Larger medtech companies in particular are continuing to invest in R&D to expand theirThe latest edition of Ernst & Young’s annual product range and global reach.medical technology industry report, Pulse of theindustry, found revenue for US and European Looking ahead, while there are significantpublic medtech companies increased just 2% opportunities to transform health care viain 2014 to US$341.8b – the second year of low, medtech, delivering on this promise andsingle-digit, top-line growth. Venture capital accelerating growth beyond the single-digitinvestment held steady, but the amount of money revenue gains achieved in 2013 and 2014dedicated to early round investment dropped will require a significant focus on and19% to less than US$1.3b. investment in innovation, right across the industry’s value chain.The disparity between the ‘haves’ and the ‘have-nots’ in medtech is growing increasingly stark. The views expressed in this article are the views of theDespite the buoyant fundraising and deal-making author, not Ernst & Young. The article provides generalenvironment that exists globally, there remains a information, does not constitute advice and should notpersistent gap in the type of early-stage venture be relied on as such. Professional advice should becapital funding required to support an innovative sought prior to any action being taken in reliance onmedtech ecosystem. any of the information. Liability limited by a scheme approved under Professional Standards Legislation.This lack of funding can be partially attributed toan increasingly uncertain reimbursement climateand the resulting pressure for companies tofind new ways to demonstrate the value of theirproducts. With its iterative product developmentcycle, medtech is particularly susceptible tovalue-based criticisms that may depress newproduct sales. As a consequence, organic growthhas been difficult to achieve, particularly at theindustry’s leading therapeutic device companies.Funding is stretched in the Australian market too,where the limited pool available is being spread Volume 26 • Number 1 • March 2016 Australasian BioTechnology 55
South Australia’smedtech capabilitiesare growing...BioSA is a high-tech innovation initiative of the South Australian Government,helping South Australian medtech companies achieve success.Contact us to find out more about our grantprograms, industry assistance and businessincubation.www.bioinnovationsa.com.au+61 8 8217 6400
AusBioFEATURE – AusMedtech 2016South Australia: partnerships between interstate and overseasA hot spot companies and local life sciences clusters tofor medtech assist them develop, test and translate newcompanies medical technology into clinical practice. An impressive number of South AustralianThe South Australian Health and Medical Research Institute forms part of medtech and biotech companies haveAdelaide BioMed City experienced exceptional growth and success to date.More and more medtech companies are Signostics, an innovator of highly miniaturisedreaping the benefits of being based in South ultrasound devices, undertakes research andAustralia. Their success comes on the back of development in Adelaide and exports to countriesa longstanding SA Government commitment to around the world. Another success story issupport and grow the sector through a vision that Jackson Care Technologies (JCT), a highly soughtcombines research, education and industry. provider of cutting-edge communications forThis commitment includes the creation of the healthcare sector. ASX-listed ReproductiveAdelaide BioMed City located at the west end of Health Science (RHS) is also a notable inclusion.North Terrace, bringing together over $3 billion The developer of advanced patented single-cellof public and private investment in research genomic technologies has launched a productand patient care infrastructure. Collaboration to improve IVF success rates through pre-between the already completed SA Health and implantation genetic screening. The companyMedical Research Institute (SAHMRI), the new has distributors in China, Russia, India, Israel,Royal Adelaide Hospital and the state’s three Turkey, Iran and South Africa and sells theuniversities offers a world-leading research, product directly in other territories.academic and clinical practice environment. These innovators are part of a growing numberJust three kilometres west of Adelaide BioMed that have received assistance and funding fromCity, researchers and innovators have long the SA Government (through BioSA and relatedbenefited from the start-up and commercial initiatives) to become commercial entities.expertise based in the Thebarton Technology Dr John Greenwood AM is grateful for thePrecinct in the city fringe suburb. The Precinct encouragement, support and advantages thatco-locates around 30 life science/medtech being based in South Australia has meant forcompanies as well as the BioSA Business his revolutionary products for burns victims.Incubator and BioSA Tech Hub facility. In “South Australia has provided me with all ofaddition, just south of the CBD, Tonsley Park the necessary infrastructure, financial supportis growing a precinct for high-value industry, and institutional encouragement to take an idearesearch, education and residential use. 10 years ago, and turn it into clinical productsA new state government initiative aimed at today,” he said. “Laboratory infrastructureboosting the presence and profitability of South and excellent animal research facilitiesAustralia’s medical technology companies is a allowed development and optimisation ofgiant leap in the right direction too. our biodegradable skin graft alternatives.The MedDev SA Alliance aims to help “BioSA provided essential support and capitalcommercialise South Australia’s medical device to safeguard continuous progress. Stateresources by bringing together manufacturers, government funding looks certain to drivethe state government, federal government and commercialisation; and Royal Adelaide Hospitalother key industry groups including BioSA recognised the importance and potential of theand the Medical Device Partnering Program at work too.”Flinders University. Another government agency, South Australia is obviously, and uniquely,Health Industries South Australia, attracts dedicated to nurturing and developing thedirect investment to the state and helps forge medtech and biotech industries. This can only be great news for interstate and international innovators with the foresight to pounce on the opportunities this level of commitment brings. The BioSA Business Incubator, located close by in Thebarton, helps to facilitate commercialisation of research coming out of the precinct. Volume 26 • Number 1 • March 2016 Australasian BioTechnology 57
AusBioNEWSChina guide to support Australianmedtech companiesAusBiotech has developed the ‘Guide for The China Guide providesAustralian medical technology companies information about IPseeking to engage in China’ (the China Guide), management, informationto support small to medium-sized Australian on business structures,medical devices and diagnostics companies the business, cultural andthat are seeking to engage with and in China. regulatory context and other information thatThe China Guide is part of a larger project a medical technologythat seeks to facilitate medical devices and company may considerdiagnostics trade and partnership with China when developing theirby breaking down the information barriers business plan for China.for Australian companies. This Guide and the The China Guide does notbroader project are supported with funding from intend to take the place ofthe Australian Trade Commission as part of the professional advice, but it is intendedAsian Business Engagement (ABE) Plan and as a starting point for Australian companieswill result in much-needed information about interested in China.intellectual property (IP) management andthe types of business structures suitable China is one of the fastest-growing andfor Australian companies in China. remarkable medtech markets in the world. Its astonishing growth is largely attributable to theAs part of the “Medical diagnostics and country’s increasing government spending,devices to China” project, AusBiotech also underpinned by robust economic growth, whichproduced an online ‘Directory of Australian has led to improved healthcare access andmedtech companies’ (the Directory) in Chinese infrastructure, as well as the ongoing expansionand English to promote Australian Medtech of public insurance coverage and infrastructurecompanies in China. The Directory includes for less developed parts of the country. Beyondcompanies developing orthopaedic, neurology the growth in government spending, patients’and cardiology devices as well as oncology ability to afford better medical care has increasedand other diagnostics and wound care and - driven by the rapidly-increasing middlehospital suppliers. Fifty Australian medtech class - and an ageing population. It is also acompanies opted to be included. The Directory complex and fast-changing environment, andis being supported by distribution in China via most importantly it is a very different businesspartner China BlueSky Partners and distributed environment to that of countries like Australia.to Chinese companies and organisations viaindustry bodies and Government departments The Guide is delivered via AusBiotech’sin Beijing, Shanghai, Nanjing and Hong Kong. AusMedtech, the national industry group that represents the medical technology sector andThe Australian medical technology industry is supported by generous in-kind support fromconsists of an estimated 500 - 800 companies major partners FB Rice and Deloitte. The projectthat are seeking opportunities in global markets was informed by a select advisory committee ofand are increasingly seeking support to enter partners that also included: The Burnet Institute,Asian markets, specifically China. Most of Quintiles, L.E.K. Consulting, Admedus Ltd,these companies are micro or small enterprises Duncan Hart Consulting, China BlueSkywith a turnover of less than $2 million, with Partners and Brandwood Biomedical.limited capability to assess overseas marketsindependently. The Guide can be requested from [email protected] and the Directory can be found at www.ausmedtechdirectory.org.au.58 Australasian BioTechnology Volume 26 • Number 1 • March 2016
AusBioNEWSWhy do academics feel they own quality?Prof Paul WoodAdjunct Professor in Biotechnology, Monash UniversityWith the recent Innovation statement we are significant capital to develop products basedagain seeing the question raised about the risk on this research.this will pose to the independence, integrity andquality of research (9 December, Quinn Grundy, A paper by Begley and Ellis in Nature (volThe Conversation). However this is only part of 483 p531-533, 2012) examined this issue ofthe story and unfortunately the other half gets reproducibility in the field of cancer researchlittle attention. and concluded that some non-reproducible papers had spawned entire fields of researchEach week there are many publications in with hundreds of secondary publications. Theypeer-reviewed quality journals with data and suggested that the pressure on academics toconclusions that will never be able to be publish could be one of the factors underlyingreproduced. Very little of this is due to deliberate the publication of erroneous, selective orfraud, but more to experiments that lack all the irreproducible data.necessary controls, are so customised in designthat other labs won’t be able to repeat them or It is time for the academic community to embracejust lack the appropriate statistical power to be the value of working with industry. It is notable to draw strong conclusions. just about the dollars that might be provided to universities, it is also about the focus onCommercial science, conducted in highly- innovation, quality and real outcomes for theregulated industries such as the pharmaceutical public who fund much of what universities do.industry, is done to a standard of quality not Research Australia conducts annual nationalimaginable in an academic environment. surveys that demonstrate a consistently high levelInternational standards such as Good Laboratory of community support for health and medicalPractice (GLP), Good Clinical Practice (GCP) and research, but if questioned further it would beGood Manufacturing Practice (GMP) are routine in no surprise to find that diagnostics, therapiesindustry, but seldom used in university research. and access to clinical trials are the activities tax payers value most.If you use the analogy of submitting a scientificpaper to a regulatory agency rather than a peer There are potential risks associated with all-reviewed journal, few academic papers would collaborations, we just need to be aware of these,get published. Firstly, none of the scientific implement appropriate systems to manage theseprotocols have been reviewed and approved up risks and accept that both academia and industryfront, the statistical analysis was not agreed to will benefit from a closer working relationship.before the experiments were conducted (datamining is not allowed) and most critically none ofthe primary data was submitted for independentanalysis.Cries of commercial interest are often heardwhen industry collaborates with universities,for example the observation that commercialstudies more frequently yield positive outcomesis evidenced as subtle commercial bias; notevidence that many companies appreciatethey have to conduct studies large enough toavoid false negatives. Freedom to publish isthe catch-cry with little concern about patentconsiderations, which are vital if industry is to risk Volume 26 • Number 1 • March 2016 Australasian BioTechnology 59
AusBioNEWSStudent life – Career opportunities vianetworkingRam Kishore Savana like an eternity as I stood alone amidst actively communicating individuals. But as it turnedProject Engineer, Medical Devices, out, at that event I met my best local guide inProtogo Medical Pty Ltd. the form of AusBiotech Membership Manager, Tanya Daw. Fortunately Tanya noticed me, spokeMaster of Biotechnology, The University of to me for a while, encouraged me and evenMelbourne; AusBiotech student volunteer introduced me to some professionals by saying some good things about me. I finally succeededI recently completed a Master of Biotechnology, in having conversations with different people untilwith a scholarship, from the University of the end of the event. This experience was theMelbourne. The program is designed to equip breakthrough that motivated me to never missbiotechnology graduates with a range of any networking events throughout my studies.management skills. During my masters, I madethe most of the networking opportunities available Change is a process that requires effort, I hadto me, in particular as a student volunteer at to break out of my comfort zone to activelyAusBiotech’s major conferences. communicate with professionals in the field (or at least try). After the first networking event,My story below might benefit some current I had a good think about the night, discussedstudents and job seekers in paving the way to networking with friends and did research on thetheir first job. purpose of a business card. I then designed a card – I called it my ‘Student Networking Card’.Life in a competitive environment is not easy for It included a short summary of my backgrounda person who had never left India. Networking and skillset in bullet points on the back of thehas been essential to building my career in card. My business cards went with me anywhereMelbourne. and everywhere.I joined AusBiotech in August 2013, the third Most of the people who’ve seen my card wereweek of my masters’ study (also my third week surprised with the idea of having a mini-resumein Melbourne) and attended my first event, Vic and appreciated my approach. This strategyBioBeers, in the same week. Every minute felt worked very well and I started receiving calls from some professionals for a coffee and had discussions abut how we could help each other. Midway through my masters, I received opportunities from two start-ups – Research assistant at a stem cell research laboratory and an intern (Engineering/Science) position at a medical device company. I chose the latter one as I was more interested in gaining hands-on experience related to my course. The medical device company, Protego Medical, is a start- up by Brandon Capital partners and has just one employee (CEO). My initial contract was for three months assisting with project management and device designing and manufacturing. As I continued to gain experience and develop my skillset, I became more confident in my work. I am working for the same company today, almost one and a half years later.60 Australasian BioTechnology Volume 26 • Number 1 • March 2016
AusBioNEWSI assisted the CEO in almost all the company biotech students from Melbourne University whoactivities that led it to reach its current stage – are members of AusBiotech were influenced byProof of Concept study at a renowned hospital in my approach and are currently participating inMelbourne. many of the events in and around Melbourne.In addition to meeting my educational goals Networking keeps students up-to-date with theand internship targets, I continued taking part in biotech industry in Melbourne while also helpingAusBiotech events. I volunteered for six national a few of the academic assignments. Whileand state-level conferences in two years. The students can aim to identify potential employersincrease in my LinkedIn contacts was directly during the networking events, the employers canproportional to the number of people I met also identify some potential employees. Havingvia networking. If I count approximately, I met seen a few others who followed this path ofmore than 400 new people in the biotech sector grabbing opportunities to gain work experience,during my two years of Masters. I also shared my I sincerely recommend every student to chooseexperience with fellow students during leisure networking as one of their main approaches totime at the university and contributed significantly land in their first job in the biotech sector. Thankto the increase in number of students attending you AusBiotech and Protego Medical!the networking events. More than half of the Volume 26 • Number 1 • March 2016 Australasian BioTechnology 61
AusBioEVENTSOpportunities to involve your companyin the International BioFest 2016Presenting three major conferences in one week, IBS 2016, the 17th Internationalthe International BioFest 2016 will be the largest- Biotechnology Symposium and Exhibition,ever gathering of the life sciences in Australia, a is a biennial gathering of the scientific andnot-to-be-missed opportunity to meet the entire industrial communities of biotechnologistsbiotech ecosystem in one place in one week. and green chemists comprising academics, researchers, students, company executives,International BioFest 2016 is expected to attract government and entrepreneurs. Theover 2,500 delegates to attend the academic, Symposium program will present the mostindustry and investor events in Melbourne advanced issues in biotechnology, greenfrom 24 – 27 October 2016. The event will be a chemistry and its related fields, which will becelebration of Australian and international life discussed by a selected group of internationalsciences and highlight Melbourne as one of the speakers and lecturers. ibs2016.orgworld’s great biotech hubs. AusBiotech 2016 will be the latest instalmentThe International BioFest 2016 will comprise: of AusBiotech’s national conference, the flagship event for Australia’s life sciences• IBS 2016, the 17th International Biotechnology sector to gather, learn and connect. Symposium and Exhibition ausbiotechnc.org• AusBiotech 2016, Australia’s life sciences Australia Biotech Invest 2016 is Australia’s conference annual life sciences investment showcase to promote investment in Australian biotech.• Australia Biotech Invest 2016, Australia’s life australiabiotechinvest.com.au sciences investment showcase. INTERNATIONALFor information about partnering with theInternational BioFest 2016 as a sponsor or BIOFEST 2016exhibitor, please refer to the website. 24 - 27 OctoberContact Kirsty Grimwade, National Conferenceand Events Manager with any questions, email Melbourne Convention Centre, [email protected]. Opportunities areavailable to partner with the full BioFest or one internationalbiofest.orgof its conferences.Speaker abstracts are currently being invitedfor IBS 2016 (submissions close 1 April),please email [email protected] forfurther information.Providing outstanding networking opportunities,BioFest events will include a welcome reception,gala conference dinner, closing event and IBShandover. AusPartnering, AusBiotech’s businessmatching app, will enable delegates to schedulemeetings with other attendees. The BioIndustryExhibition Hall will showcase more than 150companies.62 Australasian BioTechnology Volume 26 • Number 1 • March 2016
AusBioEVENTSAusBiotech 2015 in Melbournesets momentum for this year’sInternational BioFestAusBiotech 2015, held 7 -9 October at the • Industry Leadership Award – Professor MareeMelbourne Convention Centre in Victoria, was Smith, Executive Director, Centre for Integratedanother successful meeting of the Australian life Preclinical Drug Development (CIPDD)/TetraQ,sciences community, showcasing the expertise, University of Queenslandresearch and technologies to further advanceour leading biotech sector, which is currently • Emerging Company of the Year – Ellumeranked fourth in the world. Pty LtdThe conference featured an outstanding line- • Company of the Year – Spinifexup of Australian and international speakers Pharmaceuticalscovering a diverse range of topics relevant to theglobal life sciences industry, in areas including The awards recognise the leading lightsregenerative medicine, new markets, business of Australia’s world-class biotech, medicaldevelopment, access to capital, entrepreneurship, technology and healthcare sectors.biotechnology investment and clinical trials. Professor Maree Smith was recognised for herThe new one-day Regenerative Medicine stellar career as a researcher – capable of prolificSymposium focused on science’s potential discovery of novel therapeutics – and her abilityto deliver replacements for damaged tissue to achieve translation of these discoveries toand organs, and how close we are to creating clinical practice.‘made to order’ body parts. A range ofexperts – including researchers, ethicists, and Ellume Pty Ltd was named Emerging Companybiotechnology companies – discussed progress, of the Year for its development of simple, highlydevelopments and perspectives on regenerative sensitive and reliable diagnostics for infectiousmedicine and stem cell therapies. diseases, and by linking the results of those tools to optimal therapy.AusPartnering, AusBiotech’s business matchingprogram, again facilitates hundreds of meetings Spinifex Pharmaceuticals was awarded Companybetween conference participants. of the Year for its work as a pioneer in the development of new treatments for chronic painIn 2016, the AusBiotech national conference will – a debilitating and often poorly treated conditionbe part of the International BioFest, the largest- affecting millions of patients worldwide.ever gathering in Australian life sciences, withthree major conferences coming together in one The winner of the AbbVie Student Poster Awardweek in one place as one integrated network. 2015 was announced at the official closing:AusBiotech thanks all delegates, presenters, Alistair Cole, a student in the Department ofsponsors and exhibitors, in particular the Anatomy and Neuroscience at the University ofVictorian Government for their exceptional Melbourne, was named the winner of AbbViesupport as co-host of AusBiotech 2015 and the Student Poster Award 2015.upcoming AusBiotech 2016 national conference. Mr Cole received the award for his posterAward presentations at AusBiotech 2015 presentation, ‘The role of Bone Morphogenic Protein signalling in oligodendrocyteThe prestigious Johnson & Johnson Innovation differentiation and myelination.’ In layman’s2015 Industry Excellence Awards were terms, the research is an attempt to understandpresented at the opening of AusBiotech 2015: the factors involved in myelin repair in the brain and spinal cord. Volume 26 • Number 1 • March 2016 Australasian BioTechnology 63
AusBioEVENTS 12 3 4 5 6 8 7 9 10 1 and 2. Welcome to AusBiotech 2015 3. Student volunteers at AusBiotech 2015 4. Delegates plan their session attendance 5. AusPartnering business matching 6. Richard Bolt, Secretary, Department of Economic Development, Jobs, Transport and Resources, Victorian Govenment, and Dr Anna Lavelle, CEO, AusBiotech 7. Emeritus Professor Alan Trounson, Founder, MIMR-PHI Institute of Medical Research 8. Prof Kevin Hindle, Chief Executive Officer, Mentor Entrepreneurship, and Co- Founder IMENCA 9. Dr Dushyant Pathak, Associate Vice Chancellor, Office of Research Technology Management & Corporate Relations, University of California Davis 10. Professor Carola Vinuesa, Head, Department of Pathogens and Immunity, Australian National University College of Medicine, Biology and Environment.64 Australasian BioTechnology Volume 26 • Number 1 • March 2016
AusBioEVENTS11 1213 1415 16SAVE THE DATESee you back in Melbourne for AUSBIOTECH 2016 24 –26 OCTOBER (part of the International17 18 BioFest 2016) Melbourne Convention 65 Centre, Victoria For updates, bookmark ausbiotechnc.org and internationalbiofest.org 19 2011. Julie Phillips, Chair, AusBiotech, welcomes delegates to the conference dinner. 12. The Johnson & Johnson Innovation 2015 Industry Excellence Awards werepresented at the opening of AusBiotech 2015. L to R: Gavin Fox-Smith, Managing Director, Johnson & Johnson, with award winners Dr Sean Parsons, Managing Director,Ellume; Maree Smith; and Tom McCarthy, CEO, Spinifex Pharmaceuticals. 13. Lorraine Chiroiu, Chief Industry Affairs Officer, AusBiotech, and Rebecca Wilson, CEO,Buchan Consulting. 14. Dr Anna Lavelle, CEO, AusBiotech, was interviewed by Dr Fintan Walton, CEO of PharmaVentures, for Pharma TV. 15 – 17. BioIndustryExhibition Hall. 18. Alistair Cole, winner of the AbbVie Student Poster Award 2015. 19. Abbvie Student Poster Award display 20. Dr Anne Lavelle (left) waspresented with flowers by Dr Deborah Rathjen, to celebrate Anna’s 10 years leading AusBiotech. Volume 26 • Number 1 • March 2016 Australasian BioTechnology
CO-ORGANISERS HOSTLICENSING PARTNERING TECHNOLOGY TRANSFER Commercialising life science research 12 – 13 April 2016 Customs House, Brisbane, QLD ttsglobalinitiative.com.au
AusBioEVENTSTech Transfer Summit AustraliaTTS Australia 2016 will return to University of Queensland’s Customs House in Brisbane.TTS Global Initiative and AusBiotech are pleased Glenn Cross, Chief Operations Officer at AusBiotech, addresses TTSto announce the third annual Tech Transfer Australia 2015.Summit (TTS) Australia, bringing together leadingtech transfer professionals from Australia and the Thank you to TTS Australia 2015 event partnersinternational community to help build expertise Life Sciences Queensland, Johnson & Johnsonand relationships that enable successful tech Innovation, Fisher Adams Kelly, Watermark andtransfer – that which results in the translation of Global Data, and particularly UniQuest, our hostresearch into products to benefit our community. partner in both 2015 and 2016.The two-day event will return to the University TTS Australia is one chapter of a global initiative,of Queensland’s Customs House in Brisbane, with other summits in Europe and North America.with the continued support of our host partner The conference is organised by AusBiotech, viaUniQuest. its AusEventsTM division.Tech transfer activities are an essential For updates about TTS Australia 2016, bookmarkcomponent of the biotechnology sector and the website: ttsglobalinitiative.com.au.where many of Australia’s promising companiesbegan. Tech transfer offices and the TTS Australiasummits are already helping to bridge the gapbetween the world-class research going on inour universities and commercial success.Interactive presentations will highlight bestpractices, lessons learned and key issuessuch as licencing, strategic industry-researchcollaborations and commercial negotiation.Industry case studies will also be discussed.Engaging topics from TTS Australia 2015to be further explored at this year’s summitinclude international business developmentof tech transfer, commercialisation trendsin Australia, financing, reimbursement,valuing your opportunity, early-stageventuring and IP. Volume 26 • Number 1 • March 2016 Australasian BioTechnology 67
AusBioSTOCKINDEX by Joanna HillIssuer Name ASX Principal Activity First List M Cap Last Yr H $ Yr L $ EPS c PER Asset Div (c) Date $m Price $ -8 B (c)AtCor Medical 9-Nov-05Holdings Limited ACG Developer & international marketer of Blood 30.1 0.16 0.35 0.10 -2 3 Pressure at the Heart device SphygmoCorAlchemia Limited ACL Drug discovery & development Fondaparinux, 23-Dec-03 2.3 0.01 0.01 0.00 -5 0 3 9.3 antithrombotic; oncology compounds FAK 6 pathway 10 12 0 -5 2 0Acrux Limited ACR Transdermal drug delivery platform technology 29-Sep-04 111.6 0.66 1.14 0.57 7 35.2 0.06 0.15 0.04 -1 -12 1 0Actinogen Ltd ACW Developer of lead candidate Xanamem for 16-Oct-07 0 0 0 treatment of neurodegenerative dosorders uincl -2 1 Alzheimer's -3 19 0.5 -1 0Anteo Diagnostics ADO Multi-component coatings for solid phase of 7-Apr-00 69.3 0.06 0.12 0.07 -1 -6 6Limited immunoassays for biomarker development 2 4 15Adherium Ltd ADR Digital technologies - monitoring medication use 26-Aug-15 57.3 0.57 0.72 0.48 0 -28 1 in chronic respiratory conditions -5 14 8Agenix Limited AGX ThromboView clot imaging diagnostics 2-Sep-92 2.7 0.02 0.03 0.01 -1 14 100.1 0.46 1.03 0.50 -17 8 1Admedus Ltd AHZ Tissue engineering regenerative medicine & 24-Mar-04 -6 vaccine development for Herpes & HPV -1 21 -2 0Analytica Limited ALT eHealth devices. PericCoach System for Stress 25-Oct-00 3.9 0.00 0.03 0.00 -1 -8 0 Urinary Incontienence -7 -5 25 1Allegra Orthopaedics AMT Prostetic Implants tools 5-Dec-07 16.0 0.25 0.05 0.02 -1 -5 0Ltd 0 9Antisense ANP Antisense Pharmaceuticals. (Psoriasis, MS) 20-Dec-01 9.4 0.05 0.04 0.01 0Therapeitics ltd 0 17Antara Lifesiences ANR Natural, plant based therapeutics for 16-Oct-14 50.9 1.49 1.80 0.42 -5Ltd gastrointestinal diseasesAvita Medical Ltd AVH Tissue-culture, regenerative products treatemnt 11-Aug-93 55.9 0.11 0.12 0.06 -2 of wounds, scars & skin defectsAvexa Limited AVX R & D drugs for treatment of infectious diseases. 29-Sep-04 3.0 0.04 2.63 0.75 -14 HIVintergrase program & antibiotic-resistant bacterial infections.AirXpanders Ltd AXP Aeroform tissue expander for breast 22-Jun-15 231.6 1.10 2.63 0.75 -3 reconstructionBiotron Limited BIT Antiviral Drug developer, HIV & HCV 24-Jan-01 19.1 0.06 0.17 0.04 -1 19.0 0.12 1.00 0.11 -10Benitec Limited BLT Gene Silencing Technology 17-Feb-97 0.01 0.02 0.01 1.5 0Bone Medical Limited BNE Development & Commercialisation of 24-Jan-85 therapeutics for bone & joint diseaseBionomics Limited BNO Small molecule product developer in areas of 21-Dec-99 153.9 0.33 0.59 0.27 -4 cancer anxiety epilepsy & multiple sclerosisBrain Resource BRC Provider International Database for Human Brain 28-Aug-01 22.4 0.15 0.29 0.15 -2Limited FunctionBioxyne Ltd BXN Developer of treatments for respiratory diseases 14-Dec-00 4.8 0.03 0.03 0.01 0 17.6 0.02 0.04 0.02 0Cellmid Limited CDY \"Midkine - novel cancer therapeutic and 9-Dec-05 diagnostic target and anti-midkine antibodies with hybridoma cell lines and nucleotides. \"Cogstate Ltd CGS Diagnostic & therapeutic products for 13-Feb-04 66.5 0.60 0.70 0.14 0 neurodegenerative diseases (also Alzheimer's & Parkinson's)Clover Corporation CLV Refines & Supplies Natural Oils 30-Nov-99 51.2 0.31 0.60 0.14 0Limited68 Australasian BioTechnology Volume 26 • Number 1 • March 2016
AusBioSTOCKIssuer Name ASX Principal Activity First List M Cap Last Yr H $ Yr L $ EPS c PER Asset Div (c)Cochlear Ltd Date $m Price $ 35 B (c) 210 COH Manufacturer & Marketer Implants for Impaired 4-Dec-95 Hearing 5,918.6 102.49 107.25 76.73 296 316CSL Limited CSL Supply Blood Products & Vaccines 8-Jun-94 47,392.1 102.72 108.68 85.40 415 25 571 171.4636Cryosite Limited CTE Collection, Processing & Long Term Storage 9-May-02 8.9 0.19 0.44 0.19 1 20 7 1 Blood Stem CellsClinuvel CUV Developer of treatment for UV-related skin 13-Feb-01 158.2 3.70 3.64 2.50 -24 -15 25Pharmaceuticals disorders. Lead drug CUV1647 in Ph III clinicalLimited trial for the treatment of polymorphous light eruption (PLE)Cyclopharm Limited CYC Manufacturer & distributor of 18-Jan-07 35.8 0.61 0.70 0.40 6 11 11 1 radiopharmaceuticals, molecular imaging. Lead product Technegas (lung ventilation imaging drug)Cynata Therapeutics CYP Large Scale production of mesenchymal stem 20-Dec-07 25.5 0.38 1.44 0.23 -6 -6 7 cellsDorsavi Ltd DVL Motion Analysis device technologies for clinical, 11-Dec-13 54.0 0.37 0.42 0.20 -11 0 0 elite sports & OHSDimerix Ltd DXB Oraline' device for occupational & law 4-Feb-93 7.0 0.01 0.01 0.00 0 -4 1 enforcement multidrug tesing & Dimeris Ph2 ChronicKidney Disease & Diabetic RetinopathyEbos Group Ltd EBO Distributor Healthcare products 6-Dec-13 2,148.7 14.80 14.20 8.95 63 0 53 41.6111Ellex Medical Lasers ELX Production of Ophthalmic Instruments for 12-Sep-94 74.3 0.73 0.90 0.27 2 0 18 0Ltd Treatment Impaired VisionGenera Biosystems GBI Advanced Molecular Diagnostic Tests 11-Jun-08 24.9 0.26 0.36 0.20 -3 -9 -1LimitedGi Dynamics, Inc GID EndoBarrier, endoscopically delivered treatemnt 7-Sep-11 9.4 0.02 0.32 0.02 -13 0 9 for obese type 2 diabetesGenetic Technologies GTG Genomics. Genetic Technology - Non-Coding 30-Jul-87 32.6 0.02 0.06 0.02 -1 -2 1Limited DNAIDT Australia Ltd IDT Manufacturer of Pharaceuticals & clinical trial 24-Sep-93 57.0 0.25 0.42 0.14 -1 -36 0 management servicesInnate ILL Immunomodulator Microparticle technology 23-Dec-13 34.4 0.19 0.24 0.12 -3 -6 2ImunotherapeuticsLtdImmuron Ltd IMC Oral Immunotherapy treatments 30-Apr-99 24.0 0.36 0.58 0.15 -5 -8 6Imugene IMU Immuno-oncology biopharma, gastric & breast 2-Dec-93 17.3 0.01 0.02 0.01 0 -4 0 0 cancer immunotherapiesImpedimed Limited IPD Diagnostic devices: lymph oedema; muscle 24-Oct-07 292.2 0.87 1.25 0.76 -7 -13 8 wasting; metabolic disordersITL Limited ITD Innovative Medical Devices Blood Collection and 29-Oct-03 18.5 0.21 0.28 0.18 2 0 10 0.25 related marketsInvion Ltd IVX Clinical-stage developer for inlammatory 15-Feb-10 7.4 0.01 0.04 0.00 -2 0 0 respiratory diseases & high blood pressureLBT Innovations LBT Automated preparation & streaking of 31-Jul-06 12.1 0.11 0.20 0.06 0 38 2Limited microbiological specimens. MicroStreak - automated routine agar plate processingLiving Cell LCT Developer of live cell products for treatment of 1-Sep-04 25.8 0.05 0.08 0.03 -2 -3 1 neurological and metabolic disordersTechnologies LimitedLifehealthcare Group LHC Critical Care Medical Devices & Implatable 5-Dec-13 67.4 1.52 3.92 1.49 6 24 31 12.5 devicesMedTech Global Ltd MDG Healthcare software solutions, clinical 13-Aug-87 8.7 0.09 0.20 0.07 -3 -3 1 management, EMR capability, consultancy servicesMediBio MEB Diagnostic tests for depression & other mental 29-Jan-01 19.1 0.24 0.49 0.20 -17 -1 -9 health disorders Volume 26 • Number 1 • March 2016 Australasian BioTechnology 69
AusBioSTOCKIssuer Name ASX Principal Activity First List M Cap Last Yr H $ Yr L $ EPS c PER Asset Div (c)Medigard Limited Date $m Price $ -2 B (c) MGZ Medical Safety Devices. Lead products: 5-Feb-04 1.4 0.02 0.11 0.01 -1 -1 retractable hypodermic syringes; blood collection device; IV cannula/catheter introducer deviceMedical Australia MLA Distributor of Medical devices, IV system, blood 20-Dec-04 6.6 0.05 0.12 0.04 0 -28 3Limited banking lab. collection of human & animal biologicsMesoblast Limited MSB Commercialisation of adult stem cell technology 16-Dec-04 665.2 1.92 4.22 1.14 -35 -5 -3 0 with specific application in the regeneration of bone & cartilageMonash IVF Group MVF Reproductive, obstetric, gynaecological services; 26-Jun-14 383.7 1.71 1.74 1.05 9 19 -46 7.7 diagnostic & genetic testingMedical MVP Medical & Veterinary Equipment. Lead Analgesic 15-Dec-03 259.7 4.69 4.50 1.70 2 274 0 2Developments Agents (pre-hospital & emergency). PenthroxInternational Limited Inhaler.Mayne Pharma Ltd MYX Branded & generic pharma products, oral drug 29-Jun-07 990.0 1.24 1.46 0.91 3 42 4 delivery systems, complex oral dose formsNanosonics Limited NAN Disinfection & sterilisation technology, 17-May-07 531.6 1.86 2.05 1.16 -4 -51 15 decontamination products to prevent spread of infectionsNeuren NEU Bioharmaceutical therapies for brain injury, 3-Feb-05 214.6 0.12 0.17 0.07 -1 01Pharmaceuticals neurodegenerative & neurodevelopmentalLimited disordersNovogen Limited NRT Patents around ATM technology in cancer 1-Sep-94 43.0 0.10 0.45 0.10 -3 0 9 0 therapeuticsNuSep Ltd NSP Cell & protein separation systems 14-May-07 2.3 0.01 0.05 0.01 -1 0 -1OBJ Limited OBJ Magnetic micro-array drug delivery technologies 29-May-00 109.7 0.06 0.09 0.05 0 -41 0 0Orthocell Ltd OCC Regenerative cellular soft tissue therapies for 12-Aug-14 23.4 0.39 0.99 0.28 -5 -8 4 restoration of tendon, cartilage injuriesOptiscan Imaging OIL Producer Optical Instruments Laser and Optical 8-Aug-97 4.5 0.02 0.09 0.02 -1 -3 0 0Limited FibreOpthea Ltd OPT Biologics drugs for opthalmic diseases 18-Apr-91 58.6 0.19 0.28 0.07 -5 -30 15Oncosil Medical Ltd OSL Medical Radiation treatments, OncoSil silicon 15-Aug-05 67.5 0.16 0.28 0.07 -1 -26 2 & phosphorus beta emitter to be used as brachytherapyOsprey Med Inc OSP AVERT™ Plus System, to reduce dye (contrast) 2-May-12 33.9 0.23 0.85 0.19 -11 -2 14 usage in coronary & peripheral angiographic procedures, preventing induced nephropathy (CIN). Limb Recovery™ System, percutaneous technology to deliver targeted doses of antibiotics to the lower limb in patients with diabetes.Pharmaaust Ltd PAA Drug developer of synthetic compounds for 2-Oct-01 10.2 0.12 0.32 0.07 -3 -4 4 treatment of human and canine cancersPatrys Limited PAB Developer of natural human antibody based 13-Jul-07 5.6 0.01 0.02 0.01 -1 1 therapies including cancerProbiotec Limited PBP Distributor of prescription & OTC 14-Nov-06 25.9 0.47 0.55 0.15 -47 -1 40 pharmaceuticalsPrana Biotechnology PBT Commercialising research into age-related 28-Mar-00 47.0 0.09 0.26 0.07 -1 -8 7 0Limited neuro-degenerative diseases inc. Alzheimer's, Crutzfeldt-Jacobs, MND, Parkinson's. Lead compound PBT in Ph2 clinical trialsPolyNovo Ltd PNV PolyNovo Biomaterials tissue engineering & 26-Nov-98 152.5 0.29 0.34 0.07 0 0 2 Metabolic pharmaPhosphagenics POH Vital Health Science. D & C patented 11-Aug-93 13.9 0.01 0.07 0.01 -2 0 2 0Limited phosphorylation technologies, nutraceuticals, dietary supplements, Vit E phosphate complex.Prima Biomed Ltd PRR Fund Biotechnology Research (inc. cancer 23-Jun-88 82.3 0.04 0.19 0.02 -2 0 0 0 immunotherapy, rheumatoid arthritis, vaccine technology preventing parasitic diseases in animals)70 Australasian BioTechnology Volume 26 • Number 1 • March 2016
AusBioSTOCKIssuer Name ASX Principal Activity First List M Cap Last Yr H $ Yr L $ EPS c PER Asset Div (c) Date $m Price $ 0 B (c)PrescientTherapeutics Ltd PTX Immunotherapeutic products for chronic 2-Jan-92 8.1 0.09 0.13 0.05 -3 2 infectious diseases & Co-X-Gene thechnology for cancer treatemntpSivida Corp. PVA Sustained -release micro-insert drug & biologics 12-Jun-08 22.9 3.94 6.65 3.92 -86 -5 0 controlled-delivery productsPharmaxis Ltd PXS R & D & Commercialisation treatment 10-Nov-03 80.9 0.25 0.42 0.08 6 4 11 autoimmune, chronic respiratory diseases (inc. MS, cystic fibrosis, rheumatoid arthritis)Phylogica Limited PYC Discovery & Development novel peptide 30-Mar-05 24.0 0.01 0.04 0.01 0 -4 0 therapeutics for treatment of Asthma, Stroke, DiabetesResApp Health Ltd RAP Developer of SmartPhone Medical app for 12-Jan-05 63.0 0.13 0.17 0.02 0 0 0 Respiratory diseasesRegeneus Ltd RGS Developer of adipose-derived cells with 19-Sep-13 14.8 0.09 0.22 0.07 -3 -3 0 regenerative capacity for cell therapiesReproductive Health RHS Developer of chromosomal abnormality embroy 5-Mar-87 4.4 0.08 0.22 0.08 -1 -11 2Science testing in IVF cyclesResonance Health RHT MRI & tools for diagnosis and monitoring of liver 2-Jan-92 8.4 0.02 0.05 0.02 0 18 1Ltd diseases FerriScan & HepaFatResmed Inc RMD Developer Manufacturer Distributor Medical 25-Nov-99 11,157.5 8.09 9.85 6.69 33 25 0 12.367 Equipment for Diagnosis and Management of Sleep Disordered BreathingRhinomed Limited RNO BreatheAssist technology nasal device for sport, 21-Sep-07 14.9 0.02 0.06 0.02 -1 -2 0 sleep and drug deliveryRSH Respiri Ltd RSH Mobile health aplications for respiratory disorders 14-Jul-00 9.6 0.03 0.12 0.03 -2 -2 1Reva Medical, Inc RVA Bioresorbable stent products, drug-eluting 23-Dec-10 480.7 1.14 1.22 0.40 -23 -5 -17 coronary scaffolding treatment for cardiovascular diseasesSonic Healthcare SHL Diagnostic. Pathology & Radiology Services 30-Apr-87 7,527.3 18.38 23.73 16.84 93 20 -380 71LimitedSciGen Limited SIE Development Marketing Sales Pharmaceuticals 15-Nov-02 1.0 0.01 0.02 0.01 0 25 -15 (inc. Sci-B-Vac Hepatitis B vaccine)Somnomed Ltd SOM Specialises in products for sleep apnoea. Lead 27-Aug-04 139.3 2.66 3.18 2.24 1 211 25 product SomnoMed mandibular advancement splint (MAS)Starpharma Holdings SPL Global R & D Funding for Biotechnology.. 28-Sep-00 212.9 0.62 0.98 0.43 -6 -10 14Limited Commercialisation Dendrimer Nanodrugs (inc. treatment STD)Sirtex Medical SRX R & D Novel Technology for Cancer Treatment 24-Aug-00 1,832.8 32.00 41.33 14.80 86 37 149 20Limited (radioactive particles SIR-Spheres for liver cancer treatment)Suda Ltd SUD Drug delivery OroMist, oro mucosal 24-Jan-02 31.9 0.03 0.05 0.02 0 -8 1 administration for off-patent drugsSimavita Ltd SVA Wireless sensor technology solution for 22-Feb-14 8.7 0.08 0.64 0.09 -12 -1 11 assessment of urinary incontinence in the elderlyTBG Diagnosticas Ltd TDL Molecular Diagnostics 22-Dec-95 55.5 0.26 0.30 0.14 -9 -3 6Tissue Therapies TIS Developer biomedical tech. wound healing, tissue 19-Mar-04 11.8 0.04 0.25 0.03 -5 -1 1Limited regeneration, cell culture; VitoGro platform tech. enhancing cell growth & migration3D Medical Ltd 3DM 3D Printing & Holographic projection provider 30-Nov-05 21.4 0.06 0.20 0.05 -4 -2 1Universal Biosensors UBI Specialist medical in vitro diagnostic tests for 13-Dec-06 68.5 0.40 0.50 0.22 -4 -11 8Inc. point-of-care; blood test C-reactive protein testUscom Limited UCM Develop Supply Operate Medical Equipment - 10-Dec-03 16.0 0.17 0.22 0.13 -2 -11 0 Ultrasonic Cardiac Output MonitorUnilife Corporation UNS Injectable drug delivery, prefilled automatic 26-Jun-86 64.1 0.20 0.90 0.11 -26 -1 52 needle retraction syringes, wearable, autoinjectors, ocular delivery systems Volume 26 • Number 1 • March 2016 Australasian BioTechnology 71
AusBioSTOCKIssuer Name ASX Principal Activity First List M Cap Last Yr H $ Yr L $ EPS c PER Asset Div (c)Viralytics Limited VLA Date $m Price $ -29 B (c)Virtus Health Ltd Anti-cancer Virotherapy technology using 15-Oct-86 153.1 0.67 0.93 0.31 -2 12Vita Life Sciences naturally occurring Coxsackievirus and Echovirus.Limited Lead product CAVATAK VRT Assisted Reproductive Services, diagnostics, Day 11-Jun-13 480.4 6.01 7.95 4.55 38 16 -176 28 Hospitals VSC Development & distribution of 'over the counter' 23-Aug-07 82.0 1.48 1.90 0.75 8 19 40 3.75 medicines; complementary; alternative; dietary supplements; health foodsFigures displayed in above index were taken at the close of the ASX 29 February 2016.Top performers quarter rolling March 2016 Top performers year rolling March 2016ASX Company name Quarterly ASX Company name YearlyCode Polynovo Limited Return Code Resapp Health Ltd ReturnPNV % RAP 63% % 209%CGS Cogstate Ltd 54% PNV Polynovo Limited 124%RAP Resapp Health Ltd 47% CGS Cogstate Ltd 120%PBP Probiotec Limited 45% ANR Anatara Ls Ltd 120%ACL Alchemia Limited 36% AMT Allegra Orthopaedics 114%ANR Anatara Ls Ltd 34% PXS Pharmaxis Ltd 101%AXP Airxpanders, Inc. 32% PBP Probiotec Limited 93%RVA Reva Medical, Inc 32% MVP Medical Developments 84%PAA Pharmaust Limited 30% OPT Opthea Limited 83%NEU Neuren Pharmaceut. 29% BXN Bioxyne Ltd 82%VSC Vita Life Sciences. 28% ACL Alchemia Limited 79%BIT Biotron Limited 28% RVA Reva Medical, Inc 77%AGX Agenix Limited 27% ELX Ellex Medical Lasers 76%CUV Clinuvel Pharmaceut. 26% IMC Immuron Limited 59%PTX Prescient Ltd 22% OSL Oncosil Medical 58%MDG Medtech Global 22% IDT IDT Australia Ltd 54%OPT Opthea Limited 20% VLA Viralytics Limited 52%MVP Medical Developments 20% TDL Tbg Diagnostics Ltd 50%OBJ OBJ Limited 20% ACG AtCor Medical 47%NAN Nanosonics Limited 19% QRX Qrxpharma Ltd 44% LBT LBT Innovations 41% This information which has been collated by company reports released to the ASX contains general information only and does not constitute financial product advice. Baillieu Holst Stockbroking Ltd and AusBiotech make no assertions as to the merits of any investment opportunities in the companies referred to in these articles.72 Australasian BioTechnology Volume 26 • Number 1 • March 2016
AusBioPEOPLENew member profilesTransPerfect Medical Device Solutions are designed to meet all of Bioactive Laboratories is an Australian agri-biotech companythe content needs of today’s device maker, from start-up to global specialising in rare and endangered plant species for humanenterprise. Beginning with patented translation services (ISO health. Activities include drug and extract research, plant13485, ISO 14971-certified), through to e-clinical trials technology, species cultivation and the commercialisation of optimisedand validated process automation and content management plant based medicines.technology, TransPerfect offers the first comprehensive portfolio Whilst our drug development collaborations with the Walterof integrated solutions for the medical device industry. and Eliza Hall Institute and the Marshall Centre are advancingElliot Scott in the field of infectious diseases, Bioactive is continuing its(Director – ANZ) early market entry with a first-in-class, gentle to the stomach,T: +61 2 9264 0155 anti-inflammatory and pain relieving agent.E: [email protected] A watershed year for Bioactive with TGA & FDA applications advanced; a US market entry is planned in the not too distantBosch a world leading innovative company renowned for its future for a novel mouth ulcer treatment & arthritis supplement.commitment to global quality, now offers to the Australian Rick Ferdinandsmanufacturing industry the solutions to become more competitive Managing Directorin the global market through labour saving technologies utilizing T: +61 (0)414 84 9990flexible, scalable through innovative lean automation. E: [email protected] a breadth of industries and products that extend from W: www.bioactivelab.com.authe automotive industry, to healthcare, energy, power tools,household appliances and whitegoods. DEK Technologies develops cutting edge solutions acrossBosch Manufacturing Solutions division is now working with a diverse range of high technology sectors. With a globalMedical manufacturing industries throughout Australia and presence, unique business model and over 300 employeesNew Zealand offering services such as, Automation/Robotics, worldwide, DEK Technologies has successfully deliveredTest and Measurement systems, utilizing Process technologies services and products to multinational companies forin Laser Marking/Cutting, Vision systems, tightening systems, over 15 years.dispensing systems & ect. Our engineering services range from We have extensive experience in embedded systems,feasibility studies, workshops, lean equipment design, and real-time solutions, ASIC/ FPGA development, hardwareProject management through to full system integrators. design, fault tolerant systems and telecom and data-Bosch’s engineers from the Manufacturing Solutions division communication. As a growing company, diversifyingare highly skilled at understanding the entire lifecycle of into different industries, we don’t merely apply stocka project, starting at its genesis. solutions to complex challenges, but seek new ways toJohn Croft enhance the design approach and product performance.Business Development Manager DEK RechnologiesRobert Bosch (Australia) Pty. Ltd Cnr Riggall St and Maldon St Broadmeadows VIC 3047RBAU/TEF Melbourne AustraliaLocked Bag 66 P: +61 3 9309 1808Clayton South Victoria 3169 E: [email protected]: W: www.dektech.com.au1555 Centre Road, Clayton Victoria 3168T: +61 (0)3 9541 7860F: +61 (0)3 9541 7872M: +61 (0)434 185 329E: [email protected]: www.bosch-manufacturingsolutions.com.au Volume 26 • Number 1 • March 2016 Australasian BioTechnology 73
AusBioPEOPLENew member profiles (cont.)Headquartered in Adelaide, Australia, Ellex designs, develops, Celebrating 50 years of inspiring achievement, Flindersmanufactures and sells innovative product that help eye surgeons University enjoys a strong reputation for its excellencearound the world to effectively and efficiently treat eye disease. in teaching and research.Ellex is a world leader in this field. Ellex has ophthalmic lasers The flagship Medical Device Research Institute (MDRI)and devices that treat glaucoma, retinal disease primarily caused has the expertise and capabilities to deliver innovativeby diabetes, secondary cataract and vitreous opacities, as well solutions to the medical and allied health sectors.as age-related macular degeneration. Sales and service directly With dedicated programs such as the Medical Deviceto eye surgeons is conducted via subsidiary offices in Minneapolis, Partnering Program (MDPP), the Institute has formalLyon, Berlin and Tokyo. A network of more than 50 distribution avenues for collaborating with industry partners.partners around the world services other markets. Ellex expects Co-located with industry, and hosting a node of theto report a profit before tax (PBT) of $1.8m for the 6 months National Medical Technologies and Pharmaceuticalended 30 December 2015. This represents a 38% increase Industry Innovation Growth Centre (MTPConnect),on the PBT reported for the year ended 31 December 2014. the MDRI is expanding networks to further focusTom Spurling research in areas of priority.CEO Capability within the Institute is varied and cross-P: 08 8104 5200 disciplinary and our close connections to the clinicalE: [email protected] community ensure research is relevant and accessible. Carmela SergiThe National Trauma Research Institute works with organisations Institute Managernationally and internationally to prevent and reduce the impact Medical Device Research Instituteof severe injury. Through its recent integration with The Alfred Flinders University, Tonsley Bldg 1Trauma Service, NTRI provides expertise in the treatment of School of Computer Science, Engineering & Mathematicstraumatic injury and through evidence-based research, education, GPO Box 2100biotechnologies and systems development, NTRI facilitates and ADELAIDE SA 5001leads ongoing improvements in care of the injured. T: +61 8 8201 2904Biotechnologies, decision support, physiological monitoring, E: [email protected] communication and the subsequent reduction W: www.flinders.edu.au/mdriin errors of omission are the keys to improved traumacare. Currently involved in a number of biotechnology projects, The Peter MacCallum Cancer Centre houses the largestmore information about NTRI can be found at www.ntri.org.au. group of laboratory-based cancer researchers in AustraliaProfessor Mark Fitzgerald working in close collaboration with clinical cancer experts.Director Many of our laboratories have pioneered new technologiesNational Trauma Research Institute that are open to licensing and further development. We offer(a department of Alfred Health and Monash University) industry a range of opportunities for collaborative or contractLevel 4, Burnet Building research and development. Our access to sophisticated animal89 Commercial Road models of cancer and a range of human tissue banks withMelbourne Victoria 3004 associated clinical data, combined with the expertise of ourAustralia internationally-renowned research and clinical staff, providesT: +61 3 9076 8806 the ability for industry to be actively involved in novel researchW: www.ntri.org.au programs from the earliest stages.E: [email protected] Dr Shari Lofthouse Head, Intellectual Property and Business Development T: (03) 9656 3647 E: [email protected] W: www.petermac.org74 Australasian BioTechnology Volume 26 • Number 1 • March 2016
AusBioPEOPLEResApp Health is developing smartphone medical applications RSM is a full service national accounting firm delivering expertfor the diagnosis and management of respiratory disease. corporate financial and advisory accounting services to clientsThe technology is based on machine learning algorithms that across diverse industry sectors. Around the world, RSM is theuse sound alone to diagnose and measure the severity of 7th largest global audit, tax and consulting network. Our one-respiratory conditions without the need for additional hardware. firm structure enables our clients to more readily connect to ourResApp has a multi-site clinical study underway and preliminary extensive national and international networks, expertise andresults demonstrated accurate diagnosis of the majority of industry experience. We boast a national network of 29 officeschildhood respiratory diseases. Approval has been recently which, combined with over 90 years experience, has helped usreceived to extend the study to adults. Markets for ResApp’s develop an extensive understanding of Australian business trendstechnology include telehealth use, emergency department and conditions. Our network across 110 countries and 730 officesand regular clinic use, at-home use by consumers and use by enables clients to enjoy access to world’s best practice, insight andaid and humanitarian organisations in the developing world. expertise. As a single firm, we provide strong service benefits toDr Tony Keating our clients. Our structure enhances business efficiencies, reducesCEO & MD internal bureaucracy and underpins our client focused culture. ItE: [email protected] also assists our clients in readily connecting to Partners and SeniorW: www.resapphealth.com.au Advisors, providing both leading advice and great value for money. Contacts:TruScreen offers the latest technology in cervical screening, Stephen Carrollprovided real-time, accurate detection of pre-cancerous and T: (08) 9261 9100cancerous cervical tissue. TruScreen comprises a hand-held E: [email protected] and disposable single-use sensor which are gently moved Andrew Barkerover the surface of the cervix and which use low levels of T: (08) 9261 9403electricity and light to examine the cervix. E: [email protected] has been evaluated in studies involving more than10,000 women worldwide, and is proven as, or more, effective Alcidion is a leading provider of intelligent informatics forthan top quality conventional Pap tests. In addition, TruScreen high performance healthcare that empowers clinicians withdelivers its results instantly, at the point of care, eliminating the decision support tools to ensure the highest quality of careneed for expensive supporting pathology infrastructure and the for their patients. By providing clinicians with decision supportdelay in results reporting that both PAP and HPV testing incur. tools and making recommendations about patient care,Martin Dillion patient flow and patient safety, organisational efficiencyCEO may be optimised and key clinical risks eliminated.Level 1, 1 Jamison St Alcidion’s solutions target key problems for Emergency Rooms,Sydney, NSW 2000 Inpatient Services and Outpatient Departments and are builtT: +61 2 9091 7475 upon a next generation health informatics platform, whichE: [email protected] incorporates an intelligent EMR, Clinical Decision SupportW: TruScreen.com Engine & Electronic Smartforms. Alcidion Corporation Level 2, 40 Greenhill Road Wayville, SA 5034 T: +61 8 8208 4600 W: www.alcidion.com Volume 26 • Number 1 • March 2016 Australasian BioTechnology 75
AusBioPEOPLECorporate, institute and associate members of AusBiotech3M Australia Pty Ltd Australian Regenerative Business Events SydneyAbbVie Pty Ltd Medicine Institute Calimmune AustraliaAcrux Ltd Australian Synchrotron Co. Ltd Celestino Pty LimitedActinogen Limited Austrianova Singapore Pte Ltd Cell Therapies Pty LtdAdelaide Research & Innovation Avatar Brokers Pty Limited Cellmid LimitedPty Ltd Baillieu Holst Ltd Centre for Drug CandidateAdherium Limited Baker IDI Heart and Diabetes OptimisationAdmedus Limited Institute Children’s Medical ResearchAgriculture Victoria Services Bayer CropScience Pty Ltd InstitutePty Ltd Bellberry Limited China BioengineeringAinscorp Pty Ltd Benitec Biopharma Limited Technology Group LimitedAJ Park Bio21 Molecular Science Chubb Insurance Company ofAlcidion Corporation Pty Ltd and Biotechnology Institute, Australia Ltd(Australia) University of Melbourne Clarity PharmaceuticalsAlexion Pharmaceuticals Bioactive Laboratories Pty Ltd Clinical Genomics TechnologiesAustralasia P/L BioDiem Ltd Pty LtdAllens Patent & Trade Mark Biointelect Pty Ltd Clinical Network Services (CNS)Attorneys Bio-Link Australia Pty LtdAlzhyme Pty Ltd Biomedical Research Victoria Clinical Research CorporationAMGEN Australia Pty Ltd (BioMedVic) Cochlear LimitedAMS Laboratories Pty Ltd BioMelbourne Network Coloplast Pty LtdAnalytica Ltd Bionics Institute Compounds AustraliaAnteo Diagnostics Bionomics Ltd ConvaTec (Australia) Pty LtdAntisense Therapeutics Ltd BioPacific Partners Cook Australia Pty LtdANU Connect Ventures Pty Ltd BioPharmaceuticals Australia CPR Pharma Services Pty LtdAPC Technology (BPA) CSIROArnold Bloch Leibler Bioplatforms Australia Ltd CSL Behring AustraliaAstraZeneca Pty Ltd BioSA CSL LimitedATP Innovations Pty Ltd BioScience Managers Pty Ltd CTX CRC LimitedAustanz Chitin P/L Biotech Dispatch Cure Brain Cancer FoundationAustralia China Business Council BioTech Primer Inc. Curtin University - School of(ACBC) - Victoria Biotron Limited Biomedical SciencesAustralian Agricultural Company Biovite Australia Pty Ltd CV Laser Pty Ltd (CustomVis)Limited (AACo) Blueprint Life Science Group Cyclopharm LimitedAustralian Institute Bosch Australia Pty Ltd Cynata Therapeuticsfor Bioengineering & Brandon Capital Partners Cystic Fibrosis AustraliaNanotechnology (AIBN) Brandwood Biomedical Pty Ltd D3 MedicineAustralian National Fabrication Bristol-Myers Squibb (Australia) Datapharm Australia Pty LtdFacility (ANFF) Pty Ltd Davies Collison CaveAustralian National University Brooker Consulting Deakin Research Commercial(ANU) BTG Australasia P/L Deloitte Touche TohmatsuAustralian Proteome Analysis Buchan Consulting Department of EconomicFacility (APAF) Burnet Institute Development, Jobs, TransportAustralian Red Cross Blood and ResourcesService (ARCBS)76 Australasian BioTechnology Volume 26 • Number 1 • March 2016
AusBioPEOPLECorporate, institute and associate members of AusBiotechDepartment of Science, Genzyme - a Sanofi company Liberty Medical Pty LtdInformation Technology and Global Kinetics Corporation (Hollister/Dansac)Innovation (DSITI) Pty Ltd Linear Clinical Research LtdDepartment of State Growth Global Orthopaedic Technology Lipotek Pty Ltd(TAS) Gold Coast Health and Logan Office of EconomicDesignMedix, Inc. Knowledge Precinct Office DevelopmentDibbsBarker Golja Haines & Friend M. H. Carnegie & Co.Dimerix Limited Grant Thornton Australia Limited M+W GroupDLA Piper Australia Griffith Hack Madderns Patent & Trade MarkDorsaVi Pty Ltd Griffith University AttorneysEIB Insurance Brokers Pty Ltd Heidrick & Struggles Australia MasterControl Inc.Elastagen Pty Ltd Pty Ltd McCloud Consulting GroupEli Lilly Australia Pty Ltd Holman Webb Lawyers Meat and Livestock Australia LtdEllex Medical Lasers Limited Houlihan² Patent & Trade Mark Medibio LtdEllume Attorneys Medical Device ResearchELSEVIER B.V. Hydrix Pty Ltd Institute, Flinders UniversityEppendorf ide Medlab Clinical LtdERA Consulting (Australia) IDT Australia Ltd Medtronic Australasia Pty LtdPty Ltd Ikaria Australia (now part of Melbourne BiotechnologyEskitis Institute Mallinckrodt Pharmaceuticals) Melbourne Convention BureauEskitis Institute, Griffith Immuron Limited (MCB)University Imugene Ltd Melbourne School ofEY INC Research Australia Pty EngineeringFB Rice Limited Merck Sharp & DohmeFisher Adams Kelly Callinans Informit Mesoblast LimitedFitgenes Australia Pty Ltd Innate Immunotherapeutics Minomic International LimitedFlanders Investment & Trade Limited Minter Ellison Lawyers- Embassy of Belgium Institute for Glycomics Mobius Medical Pty LtdFranke Hyland Inter-K Peptide Therapeutics Monash InnovationFreehills Patent Attorneys (Inter-K Pty Ltd) Monsanto Australia Ltd.French Embassy, Trade Invion Limited Morgans Financial LimitedCommission - Business France IQ3 Corp Ltd MPR Group Pty LtdAustralia & New Zealand IQnovate Life Science Murdoch Childrens ResearchFrost & Sullivan (Australia) Organisation InstitutePty Ltd IQX Ltd Murdoch UniversityFusidium Pty Ltd Johnson & Johnson Innovation Nanosonics LimitedGamma Vaccines Pty Limited Johnson Matthey (Aust) Ltd National Association of TestingGangneung City Kain C+C Lawyers Authorities AustraliaGangwon Province King & Wood Mallesons National Trauma ResearchGarvan Institute of Medical Korea Research Institute of Institute, Alfred Health andResearch Bioscience and Biotechnology Monash UniversityGBS Venture Partners Pty Ltd KPMG NeoclinicalGenesearch Pty Ltd La Trobe University Library Neuren Pharmaceuticals LimitedGenetic Signatures LBT Innovations Ltd Neuroscience Trials Australia Volume 26 • Number 1 • March 2016 Australasian BioTechnology 77
AusBioPEOPLECorporate, institute and associate members of AusBiotechNeurosciences Victoria Ltd Provectus Biopharmaceuticals, Teva Pharmaceuticals AustraliaNew Venture Institute Inc. Pty LtdNewcastle Innovation Ltd pSivida Corp TGR Biosciences Pty LtdNewline Australia Insurance QBiotics Limited The University of QueenslandPty Ltd QIAGEN Pty Ltd The University of WesternNexvet Biopharma plc QIMR Berghofer Medical AustraliaNorton Rose Fulbright Australia Research Institute The Walter & Eliza Hall InstituteNovartis Pharmaceuticals Q-Pharm Pty Limited of Medical ResearchAustralia Pty Ltd Queensland University of THEMA Consulting Pty LtdNovo Nordisk Pharmaceuticals Technology Therapeutic Innovation AustraliaPty Ltd Quintiles Pty Ltd Tissue Therapies LtdNovogen Limited qutbluebox Pty Ltd Trajan Scientific and MedicalNovotech Regeneus Ltd TransPerfect Translations Pty LtdNucleus Network ResApp Health Limited TruScreen Pty LtdNZBIO Research Australia Limited UK Trade & InvestmentOccuRx Pty Ltd RSM Australia UniQuest Pty LtdOFX Russell Kennedy Pty Ltd Universal Biosensors Pty LtdOmnigon Pty Ltd Sanofi-Aventis University of SouthernONBoard Solutions Pty Ltd SeerPharma Pty Ltd QueenslandOncoSil Medical Ltd Sementis Limited University of Sydney,Opthea Pty Ltd Seqirus Australia - a CSL Engineering and InformationOrthocell Company TechnologiesOsprey Medical Shire Australia Pty Ltd University of Western AustraliaParanta Biosciences Limited Sienna Cancer Diagnostics Ltd University of WollongongPatheon Biologics Pty Ltd Simavita Pty Ltd UNSW - School ofPatrys Ltd SiSU Wellness Biotechnology and BiomolecularPeter MacCallum Cancer Centre SMART Arm Pty Ltd SciencesPfizer Australia Southern Star Research Pty Ltd UNSW InnovationsPharmAsia News SpeeDx Pty Ltd UoM Commercial LtdPharmaxis Ltd Spruson & Ferguson US Studies Centre, UniversityPhillips Ormonde Fitzpatrick St Vincent’s Hospital Melbourne of SydneyPhosphagenics Limited Starpharma Holdings Limited Venture ValuationPhylogica Ltd Suda Limited ViciBio Pty LtdPlanet Innovation Pty Ltd SydPath Viralytics LtdPolyNovo Limited Synchrotron Light Source Virtual Regulatory Solutions, IncPrana Biotechnology Ltd Australia WATERMARK Patent & TradePresSura Neuro Talu Ventures Mark Att.Pricewaterhouse Coopers Tasmanian Alkaloids West Pharmaceutical ServicesProtagonist Pty Ltd Telethon Kids Institute Western Sydney UniversityProteomics International Terra Rossa Capital Pty Ltd World Courier (Australia) Pty LtdLaboratories Limited Terragen Biotech Pty Ltd Wrays TetraQ78 Australasian BioTechnology Volume 26 • Number 1 • March 2016
AusBioPEOPLEAusBiotech staff and office bearersCHAIR: Ms Julie Phillips (BioDiem Ltd) Tel: (03) 9692 7240; Email: [email protected]: Ms Michelle Burke (Bristol-Myers Squibb) Tel: (03) 8523 4200; Email: [email protected] Mr Lawrence Gozlan (Scientia Capital) Tel: (03) 9661 8274; Email: [email protected] Executive Officer Dr Andrea Douglas (CSL Limited) Tel: (03) 9389 1135; Email [email protected] Assistant Mr Barry Thomas (Cook Australia Pty Ltd) Tel: (07) 3434 6010; Email [email protected] Operating Officer Ms Serina Cucuzza (Burnet Institute) Tel: 03 9282 2204; Email [email protected] Industry Affairs Officer Mr Serg Duchini (Deloitte Touche Tohmatsu) Tel: (03) 9671 7376; Email [email protected] Finance Officer & Company Dr Anna Lavelle Tel: (03) 9828 1400; Email: [email protected] Ms Jo Beamsley Tel: (03) 9828 1404; Email: [email protected] Programs Manager Mr Glenn Cross Tel: (03) 9828 1402; Email: [email protected] Services Manager Ms Lorraine Chiroiu Tel: (03) 9828 1414; Email: [email protected] Conference and Events Mrs Penny Brassington Tel: (03) 9828 1455; Email: [email protected] Manager Dr Mick Blake Tel: (03) 9828 1425; Email: [email protected] Manager Ms Tanya Daw Tel: (03) 9828 1431; Email: [email protected] Development Manager Ms Kirsty Grimwade Tel: (03) 9828 1406; Email: [email protected] and Data AdministratorEvents Coordinator Ms Jessica Italiano Tel: (03) 9828 1456; Email: [email protected] Events Coordinator Ms Hayley Laing Tel: (03) 9828 1400; Email: [email protected] Ms Mel Nelson Tel: (03) 9828 1400; Email: [email protected]/NSW Representative Ms Harshini Bellana Tel: (03) 9828 1432; Email: [email protected] Ms Sienna Deano Tel: (03) 9828 1420; Email: [email protected] Ms Amelia Lundstrom Tel: (03) 9828 1435; Email: [email protected] Ms Crystal Tan Tel: (03) 9828 1408; Email: [email protected] Mr Stephen Pattillo Tel: 0412 709 800; Email: [email protected] CHAIRS Dr Phil Kearney (Merck Sharp & Dohme) Tel: (02) 9795 9842; Email: [email protected] BranchQLD Branch Dr Ryan Parlett (Deloitte) Tel: (07) 3308 7358; Email: [email protected] Branch Mr Mathew Palmer (INC Research Australia Pty Limited) Tel: (08) 7202 1500;TAS Branch Email: [email protected] Dr Anthony Koutoulis (University of Tasmania) Tel: (03) 6226 2737;VIC Branch Email: [email protected] Branch Dr Andrea Huggins (CSL Limited) Tel: (03) 9389 1318; Email: [email protected] Mr Brian Leedman (ResApp Diagnostics) Tel: (08) 9443 4949; Email: [email protected] GROUPS Prof Paul Wood (IMNIS) Tel. 0409 098 949; Email: [email protected], AusAg & FoodtechChair, AusMedtech National Committee Mr Warren Bingham (Clinical Genomics Technologies) Tel: 0419 144 836; Email: [email protected], AusMedtech Regulatory Affairs Mr Grant Bennett (Brandwood Biomedical) Tel: (02) 9906 2984;Expert Panel Email: [email protected], AusMedtech IP Expert Panel Dr Brett Lunn (FB Rice) Tel: (02) 8231 1019; Email: [email protected], Stoma Industry GroupChair, NSW AusMedtech Dr Mick Blake (AusBiotech) Tel: (03) 9828 1425; Email: [email protected], VIC AusMedtech Ms Lis Boyce (Dibbs Barker) Tel: (02) 8233 9566; Email: [email protected] Mr Ian Reilly (Altrutec) Tel: (03) 9888 3978; Email: [email protected] Volume 26 • Number 1 • March 2016 Australasian BioTechnology 79
Celebrating life scienceswith 3 events in 1 week24 – 27 October 2016Melbourne Convention and Exhibition Centre,Melbourne, [email protected] 17th International Biotechnology IBS Symposium and Exhibition 2016 Australiawww.ibs2016.org Biotech Invest 2016AusBiotech 2016 IBS 2016 Australia’s Life ScienceAustralia’s Life Sciences 17th International Biotechnology Investment ShowcaseConference Symposium and Exhibition www.ausbiotechinvest.comwww.ausbiotechnc.org www.ibs2016.org Crown Conference CentreMelbourne Conventionand Exhibition Centre Melbourne Convention 26 – 27 October 2016 and Exhibition Centre24 – 26 October 2016 24 – 27 October 2016 SupportingHost Partners
Search
